US Stock MarketDetailed Quotes
NKGN NKGEN BIOTECH
- 1.020
- +0.042+4.24%
Close Aug 8 16:00 ET
- 1.000
- -0.020-1.96%
Post 20:01 ET
26.29MMarket Cap-269P/E (TTM)
1.020High0.960Low93.35KVolume1.000Open0.979Pre Close92.21KTurnover0.74%Turnover RatioLossP/E (Static)25.77MShares12.88052wk High-0.48P/B12.86MFloat Cap0.78052wk Low--Dividend TTM12.61MShs Float12.880Historical High--Div YieldTTM6.13%Amplitude0.780Historical Low0.987Avg Price1Lot Size
About NKGEN BIOTECH Company
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Company Profile
SymbolNKGN
Company NameNKGEN BIOTECH
Listing DateOct 2, 2023
Founded2017
CEODr. Paul Y. Song, M.D.
MarketNASDAQ
Employees63
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address3001 Daimler Street
CitySanta Ana
ProvinceCalifornia
CountryUnited States of America
Zip Code92705
Phone1-949-396-6830
Websitehttp://www.nkgenbiotech.com
Company Executives
- Name
- Position
- Salary
- Dr. Paul Y. Song, M.D.
- Chief Executive Officer and Chairman of the Board
- 3.33M
- James A. Graf
- Interim Chief Financial Officer and Principal Accounting Officer
- --
- Pierre Gagnon
- Chief Operating Officer
- 1.20M
- Dr. Yong-Man Kim, PhD
- Chief Scientific Officer
- 809.26K
- Dr. Marco Gottardis, PhD
- Director
- --
- Kathleen D. Scott
- Independent Director
- --
- Sangwoo Park
- Independent Director
- --
- Michael Klowden
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg